摘要
三阴性乳腺癌是一种侵袭性强、复发率高、易发生远处转移、预后较差且具有高度异质性的乳腺癌亚型。新辅助化疗是三阴性乳腺癌系统治疗中的重要手段。蒽环联合紫杉一直是三阴性乳腺癌新辅助化疗的常用化疗方案。近年来多项研究发现,某些细胞毒药物在三阴性特定亚型乳腺癌中表现出较好的治疗敏感性,且具有不错的临床疗效。全文就三阴性乳腺癌新辅助化疗药物研究进展进行综述。
Triple negative breast cancer（TNBC）is a subtype of breast cancer with strong invasion,high rate of recurrence and distant metastases,poor prognosis and high heterogeneity.Neoadjuvant chemotherapy is a important method of TNBC systemic treatment.The regimens of anthracycline combine with taxane are usually used in neo-adjuvant chemotherapy of TNBC.In recent years,several studies found that some of cytotoxic agents have high sensitivity and good prognosis in specific type of TNBC.A systematic review of neo-adjuvant chemotherapy medicine for TNBC was reviewed.
作者
梁晨露
杨红健
LIANG Chen-lu;YANG Hong-jian(Zhejiang Chinese Medical University,The Second Clinical Medical College,Hangzhou 310053, China;Zhejiang Cancer Hospital, Hangzhou 310022, China)
出处
《肿瘤学杂志》
CAS
2018年第3期188-194,共7页
Journal of Chinese Oncology
基金
浙江省自然科学基金(LQ17H160013)
浙江省中医药科技计划项目(2016ZB023)
关键词
三阴性乳腺癌
新辅助化疗
病理完全缓解率
triple negative breast eancer
neo-adjuvant chemotherapy
pathological completeremission rate
